Understand the Lives of People with Lupus and Launch a Product that Truly Fits Their Needs
Lupus is a complex disease with diverse manifestations, limited treatment options and inequitable impact on the affected population. This makes research into patient experience, treatment patterns, and long-term clinical outcomes particularly challenging.
At Alira Health, we have developed specialized expertise in lupus, aiding companies in addressing unmet lupus patient needs. Our aim is to drive innovation in this challenging area, especially in underserved segments and communities.
Registry data serves as a valuable resource to unlock insights and accelerate research in lupus. Comprehensive, de-identified, and complete clinical and patient experience data at your fingertips — thanks to the collaboration between Alira Health and FORWARD, the National Databank for Rheumatic Diseases — in the largest patient-reported research databank for rheumatic disorders in the US.
6,000+ lupus patients have participated in at least one survey*
*Surveys include questions relating to symptoms of systemic lupus, cutaneous lupus, and lupus nephritis
3,000+ patients with a self-reported or MD-confirmed SLE diagnosis
2,000+ patients with MD-confirmed SLE diagnosis
5 years average duration of follow-up
The lupus registry is an open cohort. Enrollment and follow-up remains active and ongoing. 75% of the registry participants have an overlap with Komodo Healthcare Map, a US claims data source.
How can you translate the insights of the lupus patient journey into value-added takeaways for your lupus asset? Watch on-demand!
We’re committed to fostering innovation and bridging the gap between observational and interventional research in lupus to ensure data accurately reflects patients’ real-life experiences.
Partner with us to benefit from:
Lupus poses ongoing challenges in both diagnosis and treatment. It has diverse manifestations, limited treatment options and inequitable impact on the affected populations. This makes research into patient experience, treatment patterns, and long-term clinical outcomes particularly challenging. We are excited to help companies increase awareness of this complex disease, expand research efforts, and improve access to care.
